Rather than ‘can we cure?’ (hepatitis C), the question is now ‘who should we cure first?’. This question is driven partly by the prohibitively high cost of Direct-acting anti-viral (DAAs) treatment. If DAAs were cheap, then anyone who wanted treatment would be given treatment—but that is not the current reality. . . .
. . . The answer to the question of who to cure ‘first’ may also be driven, in part, by the stigma and discrimination associated with injecting drugs
Anneke S. de Vos, Maria Prins and Mirjam E. E. Kretzschmar in Addiction
I have been an addiction professional and social worker since 1994. I started blogging in 2005 as the Clinical Director at Dawn Farm. I no longer work at Dawn Farm and am now the Director of Behavioral Medicine at a community hospital, and a lecturer at Eastern Michigan University’s School of Social Work.
Views expressed here are my own.
Keep in mind that the field, the contexts in which the field operates, and my views have changed over time.
View all posts by Jason Schwartz